Patent ID: 11965206
Assignee: nan
Field: Medical technology (Instruments)
Classification: CPC C  G | IPC C  G

Claim 6:
7. A computer-based method for adjusting patient phenotypes for multiple drugs and for reducing side effects from multiple drug dosing in a patient using the adjusted phenotypes, wherein the multiple drugs are inducers and/or inhibitors of CYP450 enzymes and the patient has various disease states and is in need of treatment thereof with the multiple drugs, comprising:
1) obtaining, by one or more users, tissue or fluid from a patient, analyzing the tissue or fluid, and obtaining CYP450 enzyme genotypes of the patient;
2) entering, by the one or more users into the one or more users' computer systems, names of the multiple drugs and the CYP450 enzyme genotypes of the patient, wherein a dose per drug label of each of the multiple drugs is known by the one or more users;
3) converting, by the one or more users' computer systems, the CYP450 enzyme genotypes of the patient to standard baseline phenotypes using a table of standard baseline phenotypes provided in the software of the one or more users' computer systems;
4) providing by the one or more users' computer systems, a numerical score for each of the standard baseline phenotypes using a table of scores for baseline phenotypes programmed in the one or more users' computer systems;
5) searching, by the one or more users' computer systems, one or more drug databases and identifying each of said multiple drugs that is an inducer or inhibitor of each of the CYP450 enzymes;
6) for each of the multiple drugs that is an inducer, adjusting by the one or more users' computer systems the standard baseline phenotype scores for the CYP450 enzymes which are induced using an inducer factor obtained from an inducer factor table programmed in the one or more users' computer systems, and for each of the multiple drugs that is an inhibitor, adjusting, by the one or more users' computer systems, the standard baseline phenotype scores for the CYP450 enzymes which are inhibited using an inhibitor factor obtained from an inhibitor factor table programmed in the one or more users' computer systems, thereby obtaining an adjusted phenotype score for each of the CYP450 enzymes which are induced or inhibited;
7) converting, by the one or more users' computer systems, the adjusted phenotype scores to adjusted phenotypes for each CYP450 enzyme which is induced or inhibited, using an adjusted phenotype look up table provided in the one or more users' computer systems;
8) displaying to the one or more users, by the one or more users' computer systems, adjusted phenotypes for each CYP450 enzyme which is induced or inhibited;
9) determining by the one or more users the risk of occurrence of adverse events with the use of each of these multiple drugs based upon the displayed adjusted phenotype of each CYP450 enzyme for which each of the these multiple drugs is a substrate, adjusting, by the one or more users, the dose per drug label of each of the multiple drugs based upon the determination of risk of occurrence of adverse events with the use of each of the multiple drugs, and providing the adjusted dose of the dose per drug label of each of the multiple drugs; and
10) receiving by the patient for each of the multiple drugs the adjusted dose of the dose per drug label, thereby minimizing the side effects of the multiple drug dosing in the patient,
wherein the table of standard baseline phenotypes has a range of phenotypes from poor to intermediate to normal to ultrarapid,
wherein the standard baseline phenotype scores increase in amount negatively from normal to ultrarapid, and
wherein the standard baseline phenotype scores increase in amount positively from normal to poor; and
11) further comprising identifying, by the one or more users' computer systems, whether each of said multiple drugs is a strong, medium, or weak inducer, or a strong, moderate, or weak inhibitor of each of the CYP450 enzymes.